MarketCapExport financials
AbbVie (ABBV)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
AbbVie Financial Ratios 2025-2010 | ABBV
Brief overview of AbbVie's financial ratios
Ratios are assessed across five available annual reports in the 2021–2025 interval.
Key multiples at the end of the period are P/E 220.08x (median 63.94x), EV/EBITDA 24.91x (median 22.07x), P/S 24.05x (median 5.72x). The combined multiple level is about 54.3% above the company's historical norm, leaving less valuation cushion.
The 1/P/E calculation produces a 0.5% earnings yield. It does not capture future growth or capital structure.
Current measures of operating quality are ROE -55.5%, ROA 1.4%, ROCE -4.6%. The business is not generating positive returns on invested resources. Valuation should be read cautiously until earnings recover.
The time from paying for inputs to receiving cash rose from 74.4 days to 284.2 days. Cash turnover slowed.
Overall picture
AbbVie's valuation is above historical references while efficiency remains restrained, increasing sensitivity to weak reports.
Annual Financial Ratios AbbVie
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
220.1 | 80.0 | 63.9 | 22.6 | 20.1 | 35.8 | 15.3 | 20.6 | 34.8 | 16.2 | 17.2 | 54.1 | 18.6 | 11.0 | - | - |
P/S |
24.1 | 6.1 | 5.7 | 4.6 | 4.1 | 3.6 | 3.6 | 3.6 | 6.5 | 3.8 | 3.9 | 4.8 | 4.1 | 3.2 | - | - |
EPS |
1.0 | 2.4 | 2.7 | 6.7 | 6.5 | 2.7 | 5.3 | 3.7 | 3.3 | 3.6 | 3.1 | 1.1 | 2.6 | 3.4 | 2.2 | - |
EV (Enterprise Value) |
394 B | 337 B | 298 B | 258 B | 223 B | 157 B | 178 B | 177 B | 241 B | 153 B | 129 B | 113 B | 91.8 B | 76 B | 7.41 B | -10 M |
EBITDA per Share |
8.95 | 5.6 | 7.64 | 10.7 | 10.6 | 7.22 | 10.1 | 5.51 | 6.97 | 6.64 | 5.2 | 2.64 | 4.13 | 4.42 | - | - |
EV/EBITDA |
24.9 | 34.0 | 22.1 | 13.7 | 11.9 | 13.1 | 9.8 | 18.4 | 19.2 | 12.1 | 13.3 | 24.5 | 12.5 | 9.8 | - | - |
PEG |
21.12 | -10.96 | 4.3 | 1.38 | 1.17 | 2.67 | 0.4 | 1.34 | -3.22 | 0.95 | 0.09 | -0.95 | -0.83 | 0.2 | - | - |
P/B |
3.0 | 2.5 | 2.3 | 1.9 | 1.6 | 1.1 | -14.8 | -13.8 | 36.2 | 20.8 | 22.4 | 55.1 | 17.1 | 17.3 | - | - |
P/CF |
21.0 | 18.2 | 13.6 | 10.7 | 10.2 | 9.4 | 9.5 | 9.1 | 19.6 | 14.7 | 12.6 | 32.7 | 13.3 | 9.7 | - | - |
ROE % |
-55.54 | 128.66 | 46.94 | 68.60 | 74.77 | 35.24 | -96.45 | -67.33 | 104.16 | 128.41 | 130.39 | 101.84 | 91.90 | 156.85 | - | - |
ROA % |
1.36 | 3.17 | 3.61 | 8.53 | 7.88 | 3.07 | 8.84 | 9.58 | 7.50 | 9.01 | 9.70 | 6.44 | 14.14 | 19.53 | - | - |
ROCE % |
-461.01 | 274.80 | 123.14 | 105.00 | 116.12 | 86.76 | 17.66 | 15.16 | 17.72 | 16.66 | 17.88 | 21.12 | 25.38 | 28.75 | - | - |
Current Ratio |
- | - | - | - | - | - | 3.2 | 1.0 | 1.3 | 1.7 | 1.5 | 1.4 | 2.6 | 2.3 | - | - |
DSO |
258.2 | 71.5 | 75.3 | 66.7 | 61.0 | 56.8 | 59.6 | 60.0 | 65.8 | 67.7 | 75.5 | 78.5 | 93.3 | 85.4 | - | - |
DIO |
91.6 | 89.4 | 68.6 | 70.3 | 67.3 | 60.8 | 89.0 | 75.9 | 83.2 | 90.4 | 139.4 | 92.7 | 91.6 | 88.3 | - | - |
DPO |
65.5 | 71.6 | 59.2 | 61.0 | 54.0 | 44.2 | 71.2 | 73.1 | 76.4 | 88.0 | 129.5 | 72.7 | 74.3 | 45.0 | - | - |
Operating Cycle |
349.7 | 160.9 | 143.9 | 137.0 | 128.4 | 117.5 | 148.5 | 135.9 | 149.0 | 158.1 | 215.0 | 171.2 | 184.9 | 173.7 | - | - |
Cash Conversion Cycle |
284.2 | 89.3 | 84.7 | 76.1 | 74.4 | 73.3 | 77.3 | 62.8 | 72.6 | 70.1 | 85.4 | 98.5 | 110.6 | 128.7 | - | - |
All numbers in USD currency
Quarterly Financial Ratios AbbVie
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
2.04 | 0.39 | 0.1 | 0.52 | 0.72 | 0.88 | 0.77 | 0.77 | 1 | 1.14 | 0.13 | - | 2.22 | 0.52 | 2.52 | 2.27 | 1.78 | 0.42 | 2 | 0.01 | 1.3 | -0.46 | 2.02 | 1.88 | 1.27 | 0.49 | 1.65 | -1.23 | 1.81 | 1.26 | 1.74 | 0.03 | 1.02 | 1.2 | 1.07 | 0.86 | 0.97 | 0.99 | 0.83 | 0.93 | 0.75 | 0.84 | 0.64 | -0.51 | 0.32 | 0.69 | 0.61 | 0.7 | 0.6 | 0.67 | 0.61 | 0.98 | 1.01 | 0.8 | 0.56 | - | - | - | - |
EBITDA per Share |
3.75 | 2.36 | 1.18 | 2.87 | 2.21 | 2.27 | 2.37 | 1.69 | 1.4 | 2.66 | 1.66 | - | 2.7 | 1.98 | 2.78 | - | 2.56 | 2.62 | 2.44 | - | 1.94 | 0.55 | 2.51 | - | 1.84 | 2.37 | 2.11 | - | 2.17 | 1.84 | 1.9 | - | 1.76 | 1.74 | 1.57 | - | 1.51 | 1.54 | 1.47 | - | 1.2 | 1.21 | 1.11 | - | 0.66 | 1.02 | 0.9 | - | 0.92 | 0.98 | 0.88 | - | 1.07 | 0.98 | 0.71 | - | - | - | - |
ROE % |
-590.93 | -439.49 | -403.33 | -376.21 | 153.37 | 77.47 | 67.45 | 49.16 | 56.79 | 48.42 | 60.25 | 58.45 | 84.70 | 83.47 | 83.28 | 81.67 | 55.70 | 49.94 | 38.20 | 35.30 | 0.75 | -39.95 | -43.38 | -96.45 | -40.56 | -50.03 | -64.44 | -67.33 | -87.93 | -23.41 | 37.64 | 104.16 | 133.14 | 135.61 | 132.77 | 128.41 | 136.86 | 133.80 | 133.69 | 130.39 | 45.44 | 43.08 | 71.49 | 101.84 | 173.45 | 165.86 | 126.60 | 91.90 | -373.21 | -847.53 | -1233.31 | -1507.14 | -452.86 | -362.00 | -252.29 | - | - | - | - |
ROA % |
4.01 | 2.28 | 2.86 | 3.68 | 3.92 | 4.28 | 4.69 | 3.90 | 5.77 | 7.60 | 8.87 | 8.69 | 10.82 | 8.03 | 8.55 | 7.77 | 5.04 | 4.44 | 3.43 | 3.07 | 6.19 | 6.77 | 8.09 | 8.84 | 2.63 | 5.14 | 7.65 | 9.58 | 12.73 | 10.41 | 9.77 | 7.50 | 9.53 | 9.64 | 9.37 | 9.01 | 9.76 | 9.68 | 9.82 | 9.70 | 3.89 | 3.40 | 4.81 | 6.44 | 13.25 | 14.71 | 14.38 | 14.14 | 15.98 | 18.54 | 19.58 | 19.53 | 5.87 | 4.69 | 3.27 | - | - | - | - |
ROCE % |
-2914.70 | -2543.44 | -2420.39 | -2289.71 | 419.37 | 175.29 | 147.18 | 109.37 | 103.32 | 106.95 | 100.87 | 80.07 | 111.78 | 118.40 | 125.89 | 96.98 | 121.87 | 95.90 | 88.13 | 58.20 | 26.17 | -40.32 | -82.91 | -110.46 | -147.86 | -148.54 | -141.31 | -104.48 | -51.62 | 38.01 | 117.93 | 152.31 | 203.23 | 201.87 | 198.78 | 151.55 | 199.34 | 195.35 | 186.63 | 137.49 | 192.60 | 231.79 | 262.40 | 219.63 | 250.15 | 227.39 | 169.47 | 91.92 | -364.08 | -800.89 | -1112.66 | -1141.71 | -456.00 | -406.29 | -279.43 | - | - | - | - |
DSO |
70.6 | 76.8 | 73.5 | 74.3 | 81.9 | 73.2 | 74.7 | 86.6 | 75.0 | 75.6 | 84.8 | - | 33.1 | 33.6 | 69.8 | 59.0 | 61.1 | 63.7 | 64.6 | 58.1 | 62.4 | 77.2 | 75.4 | 56.9 | 58.4 | 60.0 | 63.0 | 59.2 | 59.6 | 59.4 | 60.2 | 60.0 | 66.4 | 66.9 | 68.7 | 65.5 | 69.2 | 67.3 | 72.7 | 66.3 | 71.4 | 78.8 | 76.6 | 62.5 | 67.9 | 69.2 | 75.9 | 68.8 | 75.5 | 75.0 | 85.9 | 75.3 | 87.0 | 87.3 | 47.0 | - | - | - | - |
DIO |
108.2 | 108.0 | 85.1 | 99.6 | 102.3 | 93.9 | 91.9 | 91.7 | 56.5 | 84.9 | 84.8 | - | 28.8 | 38.1 | 74.4 | - | 67.3 | 67.2 | 71.3 | - | 59.8 | 81.4 | 120.4 | - | 86.2 | 91.0 | 92.1 | - | 79.8 | 75.7 | 76.0 | - | 90.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | 32.5 | - | - | - | 24.6 | - | - | - | 34.1 | - | - | - | 41.6 | - | - | - | 34.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | 158.6 | 173.9 | 184.2 | 167.1 | 166.6 | 178.2 | 131.6 | 160.4 | 169.7 | - | 61.9 | 71.7 | 144.2 | 59.0 | 128.4 | 130.9 | 135.8 | 58.1 | 122.2 | 158.6 | 195.8 | 56.9 | 144.6 | 150.9 | 155.1 | 59.2 | 139.5 | 135.1 | 136.2 | 60.0 | 157.0 | 66.9 | 68.7 | 65.5 | 69.2 | 67.3 | 72.7 | 66.3 | 71.4 | 78.8 | 76.6 | 62.5 | 67.9 | 69.2 | 75.9 | 68.8 | 75.5 | 75.0 | 85.9 | 75.3 | 87.0 | 87.3 | 47.0 | - | - | - | - |
Cash Conversion Cycle |
- | - | 158.6 | 173.9 | 184.2 | 167.1 | 166.6 | 178.2 | 131.6 | 160.4 | 169.7 | - | 61.9 | 71.7 | 111.8 | 59.0 | 128.4 | 130.9 | 111.2 | 58.1 | 122.2 | 158.6 | 161.7 | 56.9 | 144.6 | 150.9 | 113.4 | 59.2 | 139.5 | 135.1 | 101.3 | 60.0 | 157.0 | 66.9 | 68.7 | 65.5 | 69.2 | 67.3 | 72.7 | 66.3 | 71.4 | 78.8 | 76.6 | 62.5 | 67.9 | 69.2 | 75.9 | 68.8 | 75.5 | 75.0 | 85.9 | 75.3 | 87.0 | 87.3 | 47.0 | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company AbbVie, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
Britain
Israel
Germany
Canada
Russia
Schweiz
